18.08.2016 • NewsElaine BurridgeBayerMonsanto

Bayer Gets Limited Access to Monsanto’s Books

“In the coming weeks, CEO Werner Baumann will make a decision; namely whether...
“In the coming weeks, CEO Werner Baumann will make a decision; namely whether a friendly merger is still possible, or whether Bayer must choose an alternative path,” sources told Handelsblatt.

Monsanto is reported to have given Bayer limited access to its books after last month rejecting an improved takeover offer of $125/share, or around $65 billion. The parties have not yet signed a non-disclosure agreement, which would allow Bayer to conduct due diligence, but Monsanto is giving the German company a “limited drip” of information, according to Reuters news agency.

Sources said Bayer had no appetite to put a deal at risk by going hostile, although talks were “difficult.” An earlier news report in German business publication Handelsblatt, citing sources close to management, stated that Bayer officials were preparing to “turn directly to shareholders” to secure a deal if Monsanto insisted on a price which the Germans perceived as too risky. The US agrochemicals giant called the latest bid in July “financially inadequate.

 “In the coming weeks, CEO Werner Baumann will make a decision; namely whether a friendly merger is still possible, or whether Bayer must choose an alternative path,” sources told Handelsblatt.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.